'Triple negative' diaporamas de présentation

BIOMARKERS. Roberto Bordonaro Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania

514 views • 38 slides

Chemotherapeutic Treatment Options for Triple Negative Breast Cancer

Chemotherapeutic Treatment Options for Triple Negative Breast Cancer. Lauren Barney April 17, 2013. Breast Cancer Subtypes. Luminal A. Luminal B. Claudin -Low. Basal. HER2-enriched. ER: estrogen receptor PR: progesterone receptor HER2: human epidermal growth factor receptor 2.

781 views • 30 slides

Andere adjuvante chemotherapie bij jonge patientes met mammaca?

400 views • 29 slides

BREAST CANCER SUBTYPES: Association Between Aggressive Breast Cancer Subtypes and African Ancestry

BREAST CANCER SUBTYPES: Association Between Aggressive Breast Cancer Subtypes and African Ancestry. Lisa A. Newman, M.D., M.P.H., F.A.C.S. Professor of Surgery Director, Breast Care Center University of Michigan Ann Arbor, MI. Goals of Breast Cancer Treatment.

602 views • 29 slides

Highlights from the San Antonio Breast Cancer Symposium: Triple-Negative Breast Cancer

Highlights from the San Antonio Breast Cancer Symposium: Triple-Negative Breast Cancer. Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center. Key SABCS Abstracts on Triple Negative Breast Cancer.

1.04k views • 25 slides

537 views • 24 slides

Understanding and Treating Triple-Negative Breast Cancer

Understanding and Treating Triple-Negative Breast Cancer. Elshami M. Elamin, MD Medical Oncologist Central Care Cancer Center www.cccancer.com Wichita, KS - USA. Molecular Subtypes of Breast Cancer. Luminal A: ER+ and or PR+ Her2 -ve Luminal B: ER+ and or PR + Her2+

766 views • 14 slides

Supplemental data

Supplemental data. 3. Ex vivo irradiation (5Gy) 4. Ex vivo culture 2 hours. 1. Fresh, viable tumor . 2. Tissue slicing. 5. Formalin fixation overnight 6. Paraffin embedding overnight 7. Sectioning and drying . 8. RAD51/GEMININ immunostaining 9. Quantification of RAD51IRIF+/GEMININ+.

232 views • 9 slides

Authors: Dr. Sunil Verma Date posted: June 22 nd , 2009

151 views • 6 slides

Triple-Negative Breast Cancer Treatment Market to Witness Widespread Expansion During 2026

Triple-Negative Breast Cancer Treatment Market to Witness Widespread Expansion During 2026

37 views • 3 slides

Triple-Negative Breast Cancer Treatment Market Value Projected to Expand by 2026

According to the latest market report published by Mindaspire Market Research titled u2018Global Triple-Negative Breast Cancer Treatment Market: Global Industry Analysis, Size, Sales and Forecast By 2026,u2019 the global triple-negative breast cancer treatment market is projected to reach US$ 727 Mn by the end of 2026 and grow at a CAGR of 4.9% during the forecast period.

35 views • 3 slides

OncomiR and tumor-suppressor miR expression in triple-negative primary breast cancer.

OncomiR and tumor-suppressor miR expression in triple-negative primary breast cancer. Jelena Radojicic 1 , Apostolos Zaravinos 2 , Thomas Vrekoussis 1 , Maria Kafousi 1 , Demetrios A. Spandidos 2 , Efstathios N. Stathopoulos 1.

311 views • 1 slides